As discussed in a previous blog post, since Mayo v. Prometheus, critics of medical treatment patents have advocated that such patents should be banned from patenting. While such arguments seemed futile based on the consistent position taken by the U.S. Court of Appeals for the Federal Circuit (CAFC) that treating a disease or
Stephanie Scruggs is an experienced intellectual property attorney primarily focused on complicated patent disputes. Stephanie defends and enforces the IP rights of both U.S. and foreign-based clients in a wide range of industries, including the chemical, biochemical, pharmaceutical, electrical and mechanical fields.
M.S., Chemical Engineering
Patent Registration Number: 54,432
In a decision issued by the Federal Circuit on October 24, 2018, the court affirmed a finding by the Patent Trial and Appeal Board (PTAB) that a multiple sclerosis (MS) treatment claimed in an application owned by FWP IP APS (FWP) was not supported by adequate written description under 35 U.S.C. § 112. While the…